The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval-Reference-Cited by-同舟云学术

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

Published:2017-12 Issue:12 Volume:17 Page:e45-e53
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Kuykendall Andrew T.^ORCID,Talati Chetasi,Al Ali Najla,Sweet Kendra,Padron Eric,Sallman David A.,Lancet Jeffrey E.,List Alan F.,Zuckerman Kenneth S.,Komrokji Rami S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference11 articles.

1. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

2. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

4. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)

5. Advances in the management of myelofibrosis;Komrokji;Cancer Control,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy;Leukemia & Lymphoma;2023-04-20

2. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies;Cancer;2023-02-25

3. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis;Blood Advances;2022-03-17

4. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study;Clinical Lymphoma Myeloma and Leukemia;2021-06

5. Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies;International Journal of Molecular Sciences;2021-02-14